Address: Room 2306, Tongda International Building, Tangyan Road 41#, High-Tech Zone, Xi’an, 710065, Shaanxi, China.
Tel: +86-29-68643155/57/61
Plant source: Huperzia serrata
Product Appearance:Brown to white powder
Active Ingredient:Huperzine A
Specifications: Huperzine A 1%--99%
Product Introduction
Huperria serrata extract is a product extracted from Melaleuca and dried whole plants as raw materials. Commercially labeled extracts are usually standardized to contain 1% Huperzine A.
The folk use its whole herb to treat carbuncle swollen poison, snake bites, burns and scalds. Huperzine A, the alkaloid component in the dry-bed tower, is a potent and reversible cholinesterase inhibitor, which can improve the functional decline of senile memory, and can significantly improve the memory, cognition and behavior of patients with Alzheimer's disease Ability is a promising drug for the treatment of Alzheimer's disease.
Product Character
Plant source: Huperzia serrata
Product Appearance:Brown to white powder
Active Ingredient:Huperzine A
Specifications: Huperzine A 1%--99%
Molecular Weight: 242.32
Molecular formula: C15H18N2O
![]() | ![]() |
Production process
The Huperria serrata herb are percolated with 1-1.5% hydrochloric acid, adjusted the solution to pH 6. Flow the fluid through macroporous resin to get selected solution, washed with water and eluted with 50% ethanol, then concentrate, dried, and pulverize into powder. Dilute with ethanol, concentration the solution then dry and crush.
Function
1.Huperzine A is a highly selective anticholinesterase inhibitor that can significantly promote cholinergic transmission at nerve junctions
2. Huperzine A was used in the early treatment of myasthenia gravis. Modern pharmacological studies have shown that Huperzine A is a good medicine for the treatment of Alzheimer's disease (senile memory impairment.
It is reported that there are more than one million people with AD in the United States, and 25% of Alzheimer’s patients in Japan. A survey report in Shanghai shows that 4.5% of people over 55 in the area suffer from severe dementia and 14.4% have mild dementia. Dementia, so the market prospects of Melaleuca extract and related products are very broad.